GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018
August 02 2018 - 9:00AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will
report its second quarter 2018 financial results on Thursday August
9, 2018, and will host a conference call and webcast on Friday,
August 10, 2018, at 8:30 a.m. ET.
The dial-in number for the conference call is (844) 413-7154
(U.S. and Canada) or (216) 562-0466 (international) with
passcode 3876308. To access the live audio webcast, or the
subsequent archived recording, visit the “Investors - Events &
Presentations” section of the GlycoMimetics website at
www.glycomimetics.com. The webcast will be recorded and available
for replay on the GlycoMimetics website for 30 days following the
call.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly-owned drug candidate, GMI-1271
(uproleselan), an E-selectin antagonist, was evaluated in a Phase
1/2 clinical trial as a potential treatment for AML and is
currently being evaluated in a Phase 1 clinical trial for the
treatment of multiple myeloma. The FDA granted uproleselan
Breakthrough Therapy designation for the treatment of adult
acute myeloid leukemia (AML) patients with relapsed/refractory
disease. GlycoMimetics is also conducting a Phase 1 clinical
trial with a third drug candidate, GMI-1359, a combined CXCR4 and
E-selectin antagonist. GlycoMimetics is located
in Rockville, MD in the BioHealth Capital Region.
Learn more at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding
the clinical development of the company’s drug candidates,
including the expected timing of completion of clinical trials and
the presentation of clinical data. Actual results may differ
materially from those in these forward-looking statements. For a
further description of the risks associated with these statements,
as well as other risks facing GlycoMimetics, please see the risk
factors described in the company’s annual report on Form 10-K to be
filed with the U.S. Securities and Exchange Commission (SEC) on
March 6, 2018, and other filings GlycoMimetics makes with the SEC
from time to time. Forward-looking statements speak only as of the
date of this release, and GlycoMimetics undertakes no obligation to
update or revise these statements, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180802005005/en/
For GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024